Rationale for early intervention in acute stroke

American Journal of Cardiology

Volumn 80, Issue 4 C, 1997, Pages

  Albers, Gregory W ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

BRAIN BLOOD FLOW; BRAIN PROTECTION; CONFERENCE PAPER; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HUMAN; PRIORITY JOURNAL; STROKE;

EID: 0030876381     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00579-1     Document Type: Conference Paper

References (32)

1. Mohr JP, Sacco RL. Classification of ischemic strokes. Wolf PA, Cobb JL, D'Agostino RB. Epidemiology of stroke. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, eds. Stroke: Pathophysiology, Diagnosis, and Management, 2nd ed. New York: Churchill Livingstone, 1992:271-283.
2. National Stroke Association. Stroke remains a deadly mystery to many Americans: Gallup Study shows symptoms, causes often misunderstood by persons most at risk [press release]. Inverness, Colorado: National Stroke Association, June 5, 1996.
3. Anonymous. Activase approved for stroke in U.S. Scrip 2140; June 25, 1996:21.
4. Lassen NA. Pathophysiology of brain ischemia as it relates to the therapy of acute ischemic stroke. Clin Neuropharmacol. 13:((suppl 3)):1990;1-8.
5. Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol. 36:1994;557-565.
6. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 333:1995;1581-1587.
7. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 274:1995;1017-1025.
8. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 335:1996;145-150.
9. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet. 346:1995;1509-1514.
10. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Rosen D, Stewart-Wynne EG, Tuck RR. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA. 276:1996;961-966.
11. Activase Product Information. Physicians' Desk Reference. 51st ed. 1997;1045-1049 Medical Economics Company, Inc, Montvale, NJ.
12. Dorman PJ, Counsell CE, Sandercock PAG. Recently developed neuroprotective therapies for acute stroke: a qualitative systematic review of clinical trials. CNS Drugs. 5:1996;457-474.
13. Zivin JA, Choi DW. Stroke therapy. Sci Am. 265:1991;56-63.
14. Pulsinelli W. Pathophysiology of acute ischaemic stroke. Lancet. 339:1992;533-536.
15. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
16. Edwards K. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: results of a phase II trial. (Abstr.). Neurology. 46:1996;A424.
17. Anonymous. Cerestat beneficial in stroke. Scrip 2117;April 5, 1996:19.
18. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Stroke. 26:1995;254-258.
19. Anonymous. Clinical trials update. Scrip 2150;July 30, 1996:19.
20. Woodward RM, Huettner JE, Guastella J, Keana JFW, Weber E. In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 47:1995;568-581.
21. Anonymous. CoCensys stroke therapy in clinical trials. Scrip 1997;February 7, 1995:27.
22. Kulagowski JJ, Leeson PD. Glycine-site NMDA receptor antagonists. Exp Opin Ther Patents. 5:1995;1061-1075.
23. Warner DS, Martin H, Ludwig P, McAllister A, Keana JFW, Weber E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab. 15:1995;188-196.
24. Newell DW, Barth A, Malouf AT. Glycine site NMDA receptor antagonists provide protection against ischemia-induced neuronal damage in hippocampal slice cultures. Brain Res. 675:1995;38-44.
25. Anonymous. Clinical trials update. Scrip 2182;November 19, 1996:27.
26. Faraci FM, Brian JE. Nitric oxide and the cerebral circulation. Stroke. 25:1994;692-703.
27. Lesage AS, Peeters L, Leysen JE. Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthase pathway. J Pharmacol Exp Ther. 279:1996;749-766.
28. De Ryck M, Keersmaekers R, Duytschaever H, Claes C, Clincke G, Janssen M, Van Reet G. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther. 279:1996;748-758.
29. Buchkremer-Ratzmann I, Witte OW. Periinfarct and transhemispheric diaschisis caused by photothrombotic infarction in rat neocortex is reduced by lubeluzole but not MK-501. (Abstr.). J Cereb Blood Flow Metab. 15:((suppl 1)):1995;S381.
30. De Ryck M, De Prins E, Nolten C, Marrannes R, Clincke G. Lubeluzole improves ischemic penumbra measured by cortical spreading depression in rats. Soc Neurosci Abstr. 21:1995;1031.
31. Diener HC, Hacke W, Hennerici M, Rådberg J, Hantson L, De Keyser J. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Stroke. 27:1996;76-81.
32. Hacke W, Hennerici H, Hantson L, Diener HC. Lubeluzole - a new neuroprotectant agent in the treatment of acute ischemic stroke: results of a cardiovascular safety study in stroke patients. (Abstr.). Neurology. 46:1996;A429.